In the biotech sector,
DexCom (NASDAQ:
DXCM), a renowned player in the healthcare and medical device industry, has presented a dynamic mix of noteworthy events occurring over the last few quarters. The shares plunged by 14% in April but some analysts consider the firm as an underrated growth story in healthcare- regardless of
G7 CGM Sensor concerns and a recent leadership transition. Amid the ups and downs, various investing firms have simultaneously elevated and reduced their holdings in DexCom. Despite the firm facing additional scrutiny over safety facets of its signature G7 device,
Citigroup,
Goldman Sachs, and
BofA Securities among others have sustained their 'buy' ratings. DexCom further highlighted next-generation
CGM features at
EASD 2025 and expanded its reimbursement scheme, attracting new investments. Nonetheless, Weiss Ratings lowered DexCom's rating to 'Hold (C-)'. Weighed down by a negative hunterbrook media investigation, stake sales by insiders, and share price dips, the firm's stock extended its fall. However, it has shown resilience in defying odds, posting strong revenue growth and announcing CEO succession plans. Consequently, many investors remain optimistic about DexCom's future.
Dexcom DXCM News Analytics from Wed, 30 Apr 2025 07:00:00 GMT to Sat, 11 Oct 2025 22:25:18 GMT -
Rating 2
- Innovation 5
- Information 7
- Rumor 0
